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EDITORIAL 
BRCA1/2 mutations are the most common germline mutations, accounting for 
up to 40% of familial breast cancer (Shuen and Foulkes, 2011). BRCA1 and BRCA2 
are tumor suppressor genes identified in the early 1990s(Hall et al., 1992; Lenoir et 
al., 1991). BRCA1 mutation was found in 7% of patients at the time of breast cancer 
diagnosis in a large analysis including 3,345 patients who were aged ≤50 years. 
However, BRCA1 carriers were significantly younger (mean age 41.9 versus 44.1, P 
< 0.001), and had more ER-negative (84.1% versus 38.1%, P < 0.001) and HER2-
negative (93% versus 79%, P < 0.001) tumors (Huzarski et al., 2013).  
The high BRCA1 mutation signature expression is consistent with the relatively 
high prevalence of BRCA1 mutations in younger patients(Huzarski et al., 2013; 
Young et al., 2009). Patients with BRCA1 mutations are generally diagnosed with 
basal-like tumors(Criscitiello et al., 2012); earlier work proposed that luminal 
progenitors appear to be the cell of origin of these tumors and are regulated by c-kit 
(Lim et al., 2009). Several recent studies have reported on the landscape of somatic 
mutations in breast cancer but, very little is known regarding the pattern of somatic 
mutations in younger women. The whole genome sequencing of 100 breast tumors 
was performed but no correlation was established between total number of somatic 
base substitution and age at diagnosis in both ER-positive (P = 0.33) and ER-
negative (P = 0.14) tumors (Stephens et al., 2012). 
Several factors discriminate the biology of both breast cancer in young patients 
and the patients themselves from that of tumors and patients who are diagnosed 
later in life. There might be association between cancer and a previous pregnancy or 
pathogenesis based on a genetic predisposition; some studies suggest a direct 
connection between both cancers associated with a previous pregnancy and a 
genetic predisposition to cancer (Sigl et al., 2016). BRCA mutations occur more 
often in breast cancer (BC), but their prognostic impact on outcomes of BC has not 
been established. An updated meta-analysis on the association between BRCA 
mutations and survival in patients with BC showed median prevalence rates of 
BRCA1 and BRCA2 mutations were 14.5% and 8.3%, respectively. 
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BRCA1 and BRCA2 mutations were correlated with 
poor overall survival in patients with BC, but had no 
significant impact on breast cancer-specific survival or 
event-free survival. BC patients having BRCA1 mutation 
and treated with endocrinotherapy were found to show an 
improved survival. The results may have therapeutic and 
prognostic implications important for BRCA mutation 
carriers with BC (Zhu et al., 2016). 
The fact that young women with familial breast cancer 
syndromes appear to develop the disease more often adds 
further complexity to the biological make-up of young-onset 
breast cancer in women. Further research to reveal the 
causes for the establishment of disease in this high risk 
young population in particular is obviously warranted. 
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